Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 369

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 369
---
cause” or due to a voluntary termination of employment with “good reason” (each, as defined in the applicable option agreement) within 13 months 
 following a Change in Control (as defined in the 2019 Stock Option Plan).                                                                                                                                                       |

| (5) | Each option vested and shall vest as to 1/48th of the shares subject to the option on each monthly anniversary                                                                                                                                           
 commencing on the vesting commencement date, subject to full acceleration in the event of a Corporate Transaction (as defined in the Equity Incentive Plan) in which the surviving corporation or acquiring corporation (or its parent company) does not 
 assume or continue such outstanding awards or substitute similar awards for such outstanding awards.                                                                                                                                                     |

Equity Award Timing Procedures In accordance with Item 402(x) of Regulation S-Kunder the Securities Act, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-publicinformation (“MNPI”). We generally grant equity awards annually, and any such equity awards 245

granted are recommended by the Compensation Committee and approved by our Board on or before the grant date. We do not grant equity awards in anticipation of the release of material non-public information and do not time, and do not plan to time, the release of material non-public information in coordination with grants of equity awards in a manner that
intentionally affects the value of executive compensation. Additionally, our Insider Trading Policy prohibits directors, officers and employees from trading in our common stock while in possession of or on the basis of MNPI about us. We have not
timed, and do not plan to time, the disclosure of MNPI for the purpose of affecting the value of executive compensation.

In the year
ended December 31, 2024, no options were granted to our named executive officers within four business days prior to, or one business day following, the filing or furnishing of a periodic or current report by us that disclosed MNPI.

Equity-Based Incentive Plans

2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan

In June 2017, our Board adopted the Scilex Pharma 2017 Plan. In connection with the
corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan.

Scilex Holding Company 2019 Stock Option Plan

In May